Showing 5841-5850 of 9848 results for "".
- Aquavit Submits NDA for New Neurotoxinhttps://practicaldermatology.com/news/aquavit-submits-nda-for-new-neurotoxin/2461141/Aquavit Pharmaceuticals, Inc. has submitted its IND for a new botulinum toxin (DTX-021) to the FDA for approval. The company also unveiled its development programs at the Annual meeting of the American Academy of Dermatology in Boston. DTX-021, a botulinum toxin type A drug intende
- Dermavant's Tapinarof Shows Durable Improvement in PsO in Long-term Extension Studyhttps://practicaldermatology.com/news/dermavants-tapinarof-shows-durable-improvement-in-pso-in-long-term-extension-study/2461140/Results from the Phase 3 PSOARING 3 long-term extension study demonstrate durable improvements across efficacy outcomes, quality of life measures, and tolerability scores with investigational tapinarof cream 1% once daily (QD) for the treatment of plaque psoriasis in adults. The data, f
- Long-Term Complete Skin Clearance Data for Bimekizumab in Moderate to Severe Plaque Psoriasishttps://practicaldermatology.com/news/long-term-complete-skin-clearance-data-for-bimekizumab-in-moderate-to-severe-plaque-psoriasis/2461137/UCB presented 11 abstracts on bimekizumab in the treatment of adults with moderate to severe plaque psoriasis at the 2022 American Academy of Dermatology (AAD) Annual Meeting in Boston, MA, including a late breaking oral platform presentation and 10 posters. The platform presentation details new
- Phase 3 Data: Sun Pharma’s Winlevi Is Safe and Effective Acne Txhttps://practicaldermatology.com/news/phase-3-data-sun-pharmas-winlevi-is-safe-and-effective-acne-tx/2461134/Results from two Phase 3 pivotal clinical trials showed favorable safety and efficacy data for Winlevi (clascoterone) cream 1% in patients with acne aged 12 years and older. The findings were presented at the American Academy of Dermatol
- Timber's Topical Isotretinoin Shows Benefit Across CI Subtypeshttps://practicaldermatology.com/news/timbers-topical-isotretinoin-shows-benefit-across-ci-subtypes/2461131/TMB-001, a topical isotretinoin formulated using Timber Pharmaceuticals’ patented IPEG™ delivery system, shows benefit in the treatment of congenital ichthyosis (CI), regardless of the subtype. Findings are being presented in a late-breaking presentation of a sub-analysis of the Phase
- Tremfya Safe, Effective Across Broad Patient Subpopulations Through 5 Years: Analysishttps://practicaldermatology.com/news/tremfya-safe-effective-across-broad-patient-subpopulations-through-five-years-analysis/2461130/Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson can provide a consistent, high degree of durable skin clearance through 5 years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO), based on an
- Poster: Interim Data Show Safety, Efficacy of Adbry for More than Three Yearshttps://practicaldermatology.com/news/poster-interim-data-show-safety-efficacy-of-adbry-for-more-than-three-years/2461129/Interim data support the long-term safety and efficacy profile of Adbry™ (tralokinumab-ldrm) for up to 3.5 years in adult patients with moderate-to-severe atopic dermatitis (AD). Results were shared as a
- Compulink Partners with Promptly for New Suite of Serviceshttps://practicaldermatology.com/news/compulink-partners-with-promptly-for-new-suite-of-services/2461127/Compulink Healthcare Solutions has partnered with Promptly to launch Advantage Patient Experience™, a suite of easy-to-use features intended to provide patients with the latest in mobile device convenience, while simultaneously reducing the administrative burden on office staff.
- Janssen Launches VISIBLE Study of PsO in People of Colorhttps://practicaldermatology.com/news/janssen-launched-visible-study-of-pso-in-people-of-color/2461121/The Janssen Pharmaceutical Companies of Johnson & Johnson has initiated VISIBLE, a first-of-its-kind, large-scale prospective clinical study dedicated to people of color living with moderate to severe plaque and/or scalp psoriasis (PsO). VISIBLE will further evaluate the efficacy an
- Evommune Initiates Phase 1 Study of EVO101 for Inflammatory Skin Diseaseshttps://practicaldermatology.com/news/evommune-initiates-phase-1-study-of-evo101-for-inflammatory-skin-diseases/2461117/Evommune, Inc. has enrolled the first participant in its Phase 1 study of EVO101 in healthy volunteers. EVO101 is a novel small molecule inhibitor of interleukin 1 receptor-associated kinase 4 (IRAK4) which broadly inhibits innate inflammation and is being